Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021
Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.
Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Analysis
The Alzheimer’s Disease Drugs Market has been analyzed from 8 View Points:
1. Alzheimer’s Disease - Drugs Sales and Forecast
2. Alzheimer’s Disease - Pipeline Drugs Sales Forecast
3. Alzheimer’s Disease Drugs - Country Wise Market and Forecast
4. Alzheimer’s Disease - Country Wise Prevalence and Forecast
5. Alzheimer’s Disease – List of Pipeline Drugs in Various Phase of Development
6. Alzheimer’s Disease - Major Deals in Alzheimer’s Drugs Market
7. Alzheimer’s Disease - Funding in Alzheimer’s Disease Research
8. Alzheimer’s Disease Drugs Market – Driving Factors & Challenges
The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows:
1. Exelon
2. Razadyne/Reminyl
3. Memary
4. Ebixa
5. Aricept
6. Rivastach
7. Namenda
8. Nootropil
9. Namzaric
The 3 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows:
1. Gantenerumab
2. Crenezumab
3. Aducanumab
The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows:
1. United States
2. France
3. Germany
4. Italy
5. Spain
6. United Kingdom
7. Japan
8. China
9. India
List of Pipeline Alzheimer’s Disease Drugs in Various Phase of Development
1. Phase I
2. Phase II
3. Phase III
The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows:
1. Strategic Alliance
2. Licensing Agreement
3. Collaboration Deals
4. Mergers and Acquisitions
Data Source
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Analysis
- In 2016, the global market for Alzheimer’s disease drugs was dominated by Namenda, Memary, Aricept and Exelon. The combined market share of these four drugs was over 80% in the year 2016.
- Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer’s disease market.
- With the patent expiration of popular drugs the sales of the Alzheimer’s drugs have also declined. However, there are several pipeline drugs like Gantenerumab, Crenezumab and Aducanumab among others which are likely to hit the market during the period 2019 - 2020.
- In the Alzheimer’s disease drugs market, the United States is the largest market.
- Japan is the second leading market for Alzheimer’s disease drugs market accounting for XXX% market share in 2016.
- China stands at the third spot in the global Alzheimer’s disease drugs market being followed by India with XXX% share in the same year.
- The EU5 countries together accounted for over 10% share of the global Alzheimer’s disease drugs market in 2016.
The Alzheimer’s Disease Drugs Market has been analyzed from 8 View Points:
1. Alzheimer’s Disease - Drugs Sales and Forecast
2. Alzheimer’s Disease - Pipeline Drugs Sales Forecast
3. Alzheimer’s Disease Drugs - Country Wise Market and Forecast
4. Alzheimer’s Disease - Country Wise Prevalence and Forecast
5. Alzheimer’s Disease – List of Pipeline Drugs in Various Phase of Development
6. Alzheimer’s Disease - Major Deals in Alzheimer’s Drugs Market
7. Alzheimer’s Disease - Funding in Alzheimer’s Disease Research
8. Alzheimer’s Disease Drugs Market – Driving Factors & Challenges
The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows:
1. Exelon
2. Razadyne/Reminyl
3. Memary
4. Ebixa
5. Aricept
6. Rivastach
7. Namenda
8. Nootropil
9. Namzaric
The 3 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows:
1. Gantenerumab
2. Crenezumab
3. Aducanumab
The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows:
1. United States
2. France
3. Germany
4. Italy
5. Spain
6. United Kingdom
7. Japan
8. China
9. India
List of Pipeline Alzheimer’s Disease Drugs in Various Phase of Development
1. Phase I
2. Phase II
3. Phase III
The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows:
1. Strategic Alliance
2. Licensing Agreement
3. Collaboration Deals
4. Mergers and Acquisitions
Data Source
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
1. EXECUTIVE SUMMARY
2. GLOBAL ALZHEIMER’S DISEASE - DRUGS MARKET AND PREVALENCE ANALYSIS
2.1 Global Alzheimer’s Disease - Drugs Market and Forecast (2010 - 2021)
2.2 Global Alzheimer’s Disease - Prevalence and Forecast (2010 - 2021)
3. GLOBAL ALZHEIMER’S DISEASE - COUNTRY WISE MARKET SHARE AND FORECAST (2013 - 2021)
4. GLOBAL ALZHEIMER’S DISEASE - DRUGS SALES AND FORECAST TO 2021
4.1 Exelon (Rivastigmine) Sales and Forecast
4.2 Razadyne/Reminyl Sales and Forecast
4.3 Memary (Memantine) Sales and Forecast
4.4 Ebixa (Memantine) Sales and Forecast
4.5 Aricept (Donepezil) Sales and Forecast
4.6 Rivastach Sales and Forecast
4.7 Namenda (Memantine) Sales and Forecast
4.8 Nootropil (Piracetam) Sales and Forecast
4.9 Namzaric (Memantine and Donepezil) Sales and Forecast
5. GLOBAL ALZHEIMER’S DISEASE - PIPELINE DRUGS ANALYSIS AND SALES FORECAST
5.1 Gantenerumab Drugs Analysis and Sales Forecast
5.1.1 About Gantenerumab
5.1.2 Clinical Trials
5.1.3 Gantenerumab Drugs Sales Forecast
5.2 Crenezumab Drugs Analysis and Sales Forecast
5.2.1 About Crenezumab
5.2.2 Clinical Trials
5.2.3 Crenezumab Drugs Sales Forecast
5.3 Aducanumab (BIIB037) Drugs Analysis and Sales Forecast
5.3.1 About BIIB037
5.3.2 Clinical Trials
5.3.3 Aducanumab (BIIB037) Drugs Sales Forecast
6. ALZHEIMER’S DISEASE DRUGS MARKET AND PREVALENCE - COUNTRY WISE ANALYSIS
6.1 United States - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.1.1 United States - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.1.2 United States - Alzheimer’s Disease Prevalence and Forecast (2010 - 2021)
6.2 France - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.2.1 France - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.2.2 France - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.3 Germany - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.3.1 Germany - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.3.2 Germany - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.4 Italy - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.4.1 Italy - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.4.2 Italy - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.5 Spain - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.5.1 Spain - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.5.2 Spain - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.6 United Kingdom - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.6.1 United Kingdom - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.6.2 United Kingdom - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.7 Japan - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.7.1 Japan - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.7.2 Japan - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.8 China - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.8.1 China - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.8.2 China - Alzheimer’s Disease Prevalence and Forecast (2010 - 2021)
6.9 India - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.9.1 India - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.9.2 India - Alzheimer’s Disease Prevalence and Forecast (2010 - 2021)
7. ALZHEIMER'S DISEASE DRUG DEVELOPMENT PIPELINE: 2017
7.1 Agents Currently in Phase I of Alzheimer's Disease Drug Development (May 2017)
7.2 Agents Currently in Phase II of Alzheimer's Disease Drug Development (May 2017)
7.3 Agents Currently in Phase III of Alzheimer's Disease Drug Development (May 2017)
7.4 Immunotherapies in Clinical Trials for Alzheimer's Disease (May 2017)
8. GLOBAL ALZHEIMER’S DISEASE DRUGS MARKET - MAJOR DEALS ANALYSIS
8.1 Global Alzheimer’s Disease Drugs Market - Strategic Alliance
8.2 Global Alzheimer’s Disease Drugs Market - Licensing Agreement
8.3 Global Alzheimer’s Disease Drugs Market - Collaboration Deals
8.4 Global Alzheimer’s Disease Drugs Market - Mergers and Acquisitions
9. GLOBAL ALZHEIMER’S DISEASE DRUGS RESEARCH - FUNDING ANALYSIS
9.1 National Institute of Health (2011 - 2018)
9.2 Alzheimer's Association (2011 - 2016)
9.3 Cure Alzheimer’s Fund (2008 - 2016)
9.4 Alzheimer’s Drug Discovery Foundation (2008 - 2016)
9.5 BrightFocus Foundation (2010 - 2016)
10. GLOBAL ALZHEIMER’S DISEASE DRUG MARKET - DRIVING FACTORS
10.1 Growing Aging Population
10.1.1 Global Ageing Indicators
10.1.2 Population Aged 60 or Over: World and Development Regions, 1950 - 2050
10.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 - 2050
10.2 Unmet Medical Needs
10.3 Pipeline Candidate Expected to Drive Alzheimer’s Disease Drugs Market
10.4 Future Drugs for Disease Modification in Alzheimer’s Disease
11. GLOBAL ALZHEIMER’S DISEASE DRUG MARKET - CHALLENGES
11.1 Lack of Validated Targets & Lack of Animal Models
11.2 Barriers in the Design and Implementation of Clinical Trials
11.3 Barriers in Academia & Regulatory Issues
11.4 Alzheimer’s Drug Failure: Insinuation for Future R&D in Neuroscience
11.5 Costly Alzheimer’s Drug Development Dissuade Drug Companies
11.6 Research Setbacks and Stepping Stones
11.7 Country Wise Barriers to Growth for Alzheimer’s Disease Drugs Market
11.7.1 United States
11.7.2 France
11.7.3 Germany
11.7.4 United Kingdom
11.7.5 Japan
11.7.6 China
11.7.7 India
2. GLOBAL ALZHEIMER’S DISEASE - DRUGS MARKET AND PREVALENCE ANALYSIS
2.1 Global Alzheimer’s Disease - Drugs Market and Forecast (2010 - 2021)
2.2 Global Alzheimer’s Disease - Prevalence and Forecast (2010 - 2021)
3. GLOBAL ALZHEIMER’S DISEASE - COUNTRY WISE MARKET SHARE AND FORECAST (2013 - 2021)
4. GLOBAL ALZHEIMER’S DISEASE - DRUGS SALES AND FORECAST TO 2021
4.1 Exelon (Rivastigmine) Sales and Forecast
4.2 Razadyne/Reminyl Sales and Forecast
4.3 Memary (Memantine) Sales and Forecast
4.4 Ebixa (Memantine) Sales and Forecast
4.5 Aricept (Donepezil) Sales and Forecast
4.6 Rivastach Sales and Forecast
4.7 Namenda (Memantine) Sales and Forecast
4.8 Nootropil (Piracetam) Sales and Forecast
4.9 Namzaric (Memantine and Donepezil) Sales and Forecast
5. GLOBAL ALZHEIMER’S DISEASE - PIPELINE DRUGS ANALYSIS AND SALES FORECAST
5.1 Gantenerumab Drugs Analysis and Sales Forecast
5.1.1 About Gantenerumab
5.1.2 Clinical Trials
5.1.3 Gantenerumab Drugs Sales Forecast
5.2 Crenezumab Drugs Analysis and Sales Forecast
5.2.1 About Crenezumab
5.2.2 Clinical Trials
5.2.3 Crenezumab Drugs Sales Forecast
5.3 Aducanumab (BIIB037) Drugs Analysis and Sales Forecast
5.3.1 About BIIB037
5.3.2 Clinical Trials
5.3.3 Aducanumab (BIIB037) Drugs Sales Forecast
6. ALZHEIMER’S DISEASE DRUGS MARKET AND PREVALENCE - COUNTRY WISE ANALYSIS
6.1 United States - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.1.1 United States - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.1.2 United States - Alzheimer’s Disease Prevalence and Forecast (2010 - 2021)
6.2 France - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.2.1 France - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.2.2 France - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.3 Germany - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.3.1 Germany - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.3.2 Germany - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.4 Italy - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.4.1 Italy - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.4.2 Italy - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.5 Spain - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.5.1 Spain - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.5.2 Spain - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.6 United Kingdom - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.6.1 United Kingdom - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.6.2 United Kingdom - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.7 Japan - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.7.1 Japan - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.7.2 Japan - Alzheimer’s Disease Prevalence and Forecast (2012 - 2021)
6.8 China - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.8.1 China - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.8.2 China - Alzheimer’s Disease Prevalence and Forecast (2010 - 2021)
6.9 India - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.9.1 India - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2021)
6.9.2 India - Alzheimer’s Disease Prevalence and Forecast (2010 - 2021)
7. ALZHEIMER'S DISEASE DRUG DEVELOPMENT PIPELINE: 2017
7.1 Agents Currently in Phase I of Alzheimer's Disease Drug Development (May 2017)
7.2 Agents Currently in Phase II of Alzheimer's Disease Drug Development (May 2017)
7.3 Agents Currently in Phase III of Alzheimer's Disease Drug Development (May 2017)
7.4 Immunotherapies in Clinical Trials for Alzheimer's Disease (May 2017)
8. GLOBAL ALZHEIMER’S DISEASE DRUGS MARKET - MAJOR DEALS ANALYSIS
8.1 Global Alzheimer’s Disease Drugs Market - Strategic Alliance
8.2 Global Alzheimer’s Disease Drugs Market - Licensing Agreement
8.3 Global Alzheimer’s Disease Drugs Market - Collaboration Deals
8.4 Global Alzheimer’s Disease Drugs Market - Mergers and Acquisitions
9. GLOBAL ALZHEIMER’S DISEASE DRUGS RESEARCH - FUNDING ANALYSIS
9.1 National Institute of Health (2011 - 2018)
9.2 Alzheimer's Association (2011 - 2016)
9.3 Cure Alzheimer’s Fund (2008 - 2016)
9.4 Alzheimer’s Drug Discovery Foundation (2008 - 2016)
9.5 BrightFocus Foundation (2010 - 2016)
10. GLOBAL ALZHEIMER’S DISEASE DRUG MARKET - DRIVING FACTORS
10.1 Growing Aging Population
10.1.1 Global Ageing Indicators
10.1.2 Population Aged 60 or Over: World and Development Regions, 1950 - 2050
10.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 - 2050
10.2 Unmet Medical Needs
10.3 Pipeline Candidate Expected to Drive Alzheimer’s Disease Drugs Market
10.4 Future Drugs for Disease Modification in Alzheimer’s Disease
11. GLOBAL ALZHEIMER’S DISEASE DRUG MARKET - CHALLENGES
11.1 Lack of Validated Targets & Lack of Animal Models
11.2 Barriers in the Design and Implementation of Clinical Trials
11.3 Barriers in Academia & Regulatory Issues
11.4 Alzheimer’s Drug Failure: Insinuation for Future R&D in Neuroscience
11.5 Costly Alzheimer’s Drug Development Dissuade Drug Companies
11.6 Research Setbacks and Stepping Stones
11.7 Country Wise Barriers to Growth for Alzheimer’s Disease Drugs Market
11.7.1 United States
11.7.2 France
11.7.3 Germany
11.7.4 United Kingdom
11.7.5 Japan
11.7.6 China
11.7.7 India
LIST OF FIGURES:
Figure 2-1: Global - Alzheimer’s Disease Drugs Market (Million US$), 2010 - 2016
Figure 2-2: Global - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 2-3: Global - Alzheimer’s Disease Prevalence (Million), 2010 - 2016
Figure 2-4: Global - Forecast for Alzheimer’s Disease Prevalence (Million), 2017 - 2021
Figure 4-1: Global - Exelon Drugs Sales (Million US$), 2003 - 2016
Figure 4-2: Global - Forecast for Exelon Drugs Sales (Million US$), 2017 - 2021
Figure 4-3: Global - Razadyne/Reminyl Drugs Sales (Million US$), 2010 - 2016
Figure 4-4: Global - Forecast for Razadyne/Reminyl Drugs Sales (Million US$), 2017 - 2021
Figure 4-5: Global - Memary Drugs Sales (Million US$), 2011 - 2016
Figure 4-6: Global - Forecast for Memary Drugs Sales (Million US$), 2017 - 2021
Figure 4-7: Global - Ebixa Drugs Sales (Million US$), 2003 - 2016
Figure 4-8: Global - Forecast for Ebixa Drugs Sales (Million US$), 2017 - 2021
Figure 4-9: Global - Aricept Drugs Sales (Million US$), 2009 - 2016
Figure 4-10: Global - Forecast for Aricept Drugs Sales (Million US$), 2017 - 2021
Figure 4-11: Global - Rivastach Drugs Sales (Million US$), 2011 - 2016
Figure 4-12: Global - Forecast for Rivastach Drugs Sales (Million US$), 2017 - 2021
Figure 4-13: Global - Namenda Drugs Sales (Million US$), 2003 - 2016
Figure 4-14: Global - Forecast for Namenda Drugs Sales (Million US$), 2017 - 2021
Figure 4-15: Global - Nootropil Drugs Sales (Million US$), 2004 - 2016
Figure 4-16: Global - Forecast for Nootropil Drugs Sales (Million US$), 2017 - 2021
Figure 4-17: Global - Namzaric Drugs Sales (Million US$), 2015 - 2016
Figure 4-18: Global - Forecast for Namzaric Drugs Sales (Million US$), 2017 - 2021
Figure 5-1: Global - Forecast for Gantenerumab Drugs Sales (Million US$), 2019 - 2021
Figure 5-2: Global - Forecast for Crenezumab Drugs Sales (Million US$), 2019 - 2021
Figure 5-3: Global - Forecast for Aducanumab (BIIB037) Drugs Sales (Million US$), 2020 - 2021
Figure 6-1: United States - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-2: United States - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-3: United States - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2016
Figure 6-4: United States - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-5: France - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-6: France - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-7: France - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-8: France - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-9: Germany - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-10: Germany - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-11: Germany - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-12: Germany - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-13: Italy - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-14: Italy - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-15: Italy - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-16: Italy - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-17: Spain - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-18: Spain - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-19: Spain - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-20: Spain - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-21: United Kingdom - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-22: United Kingdom - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-23: United Kingdom - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-24: United Kingdom - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-25: Japan - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-26: Japan - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-27: Japan - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2016
Figure 6-28: Japan - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-29: China - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-30: China - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-31: China - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2016
Figure 6-32: China - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-33: India - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-34: India - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-35: India - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2016
Figure 6-36: India - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 7-1: Alzheimer's Disease Drug Development - All agents currently in the Pipeline, 2017
Figure 7-2: Alzheimer’s Disease - Mechanisms of Action of Agents in phase II, 2017
Figure 7-3: Alzheimer’s Disease - Mechanisms of Action of Agents in phase III, 2017
Figure 9-1: National Institute of Health - Alzheimer’s Disease Research Funding (Million US$), 2011 - 2016
Figure 9-2: National Institute of Health - Forecast for Alzheimer’s Disease Research Funding (Million US$), 2017 - 2018
Figure 9-3: Alzheimer’s Association - Alzheimer’s Disease Research Funding (Million US$), 2011 - 2016
Figure 9-4: Cure Alzheimer’s Fund - Alzheimer’s Disease Research Funding (Million US$), 2008 - 2016
Figure 9-5: Alzheimer’s Drug Discovery Foundation - Alzheimer’s Disease Research Funding (Million US$), 2008 - 2016
Figure 10-1: Worldwide - Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
Figure 10-2: Worldwide - Old-Age Dependency Ratio: Major Areas, 2009 & 2050
Figure 10-3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 - 2050
Figure 10-4: Global - Forecast for Alzheimer’s Disease Pipeline Drugs Market (Million US$), 2019 - 2021
Figure 11-1: Unsuccessful Alzheimer’s Drug Development (Number), 1998 - 2011
Figure 2-1: Global - Alzheimer’s Disease Drugs Market (Million US$), 2010 - 2016
Figure 2-2: Global - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 2-3: Global - Alzheimer’s Disease Prevalence (Million), 2010 - 2016
Figure 2-4: Global - Forecast for Alzheimer’s Disease Prevalence (Million), 2017 - 2021
Figure 4-1: Global - Exelon Drugs Sales (Million US$), 2003 - 2016
Figure 4-2: Global - Forecast for Exelon Drugs Sales (Million US$), 2017 - 2021
Figure 4-3: Global - Razadyne/Reminyl Drugs Sales (Million US$), 2010 - 2016
Figure 4-4: Global - Forecast for Razadyne/Reminyl Drugs Sales (Million US$), 2017 - 2021
Figure 4-5: Global - Memary Drugs Sales (Million US$), 2011 - 2016
Figure 4-6: Global - Forecast for Memary Drugs Sales (Million US$), 2017 - 2021
Figure 4-7: Global - Ebixa Drugs Sales (Million US$), 2003 - 2016
Figure 4-8: Global - Forecast for Ebixa Drugs Sales (Million US$), 2017 - 2021
Figure 4-9: Global - Aricept Drugs Sales (Million US$), 2009 - 2016
Figure 4-10: Global - Forecast for Aricept Drugs Sales (Million US$), 2017 - 2021
Figure 4-11: Global - Rivastach Drugs Sales (Million US$), 2011 - 2016
Figure 4-12: Global - Forecast for Rivastach Drugs Sales (Million US$), 2017 - 2021
Figure 4-13: Global - Namenda Drugs Sales (Million US$), 2003 - 2016
Figure 4-14: Global - Forecast for Namenda Drugs Sales (Million US$), 2017 - 2021
Figure 4-15: Global - Nootropil Drugs Sales (Million US$), 2004 - 2016
Figure 4-16: Global - Forecast for Nootropil Drugs Sales (Million US$), 2017 - 2021
Figure 4-17: Global - Namzaric Drugs Sales (Million US$), 2015 - 2016
Figure 4-18: Global - Forecast for Namzaric Drugs Sales (Million US$), 2017 - 2021
Figure 5-1: Global - Forecast for Gantenerumab Drugs Sales (Million US$), 2019 - 2021
Figure 5-2: Global - Forecast for Crenezumab Drugs Sales (Million US$), 2019 - 2021
Figure 5-3: Global - Forecast for Aducanumab (BIIB037) Drugs Sales (Million US$), 2020 - 2021
Figure 6-1: United States - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-2: United States - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-3: United States - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2016
Figure 6-4: United States - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-5: France - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-6: France - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-7: France - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-8: France - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-9: Germany - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-10: Germany - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-11: Germany - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-12: Germany - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-13: Italy - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-14: Italy - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-15: Italy - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-16: Italy - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-17: Spain - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-18: Spain - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-19: Spain - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-20: Spain - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-21: United Kingdom - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-22: United Kingdom - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-23: United Kingdom - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2016
Figure 6-24: United Kingdom - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-25: Japan - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-26: Japan - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-27: Japan - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2016
Figure 6-28: Japan - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-29: China - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-30: China - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-31: China - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2016
Figure 6-32: China - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 6-33: India - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2016
Figure 6-34: India - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 6-35: India - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2016
Figure 6-36: India - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2017 - 2021
Figure 7-1: Alzheimer's Disease Drug Development - All agents currently in the Pipeline, 2017
Figure 7-2: Alzheimer’s Disease - Mechanisms of Action of Agents in phase II, 2017
Figure 7-3: Alzheimer’s Disease - Mechanisms of Action of Agents in phase III, 2017
Figure 9-1: National Institute of Health - Alzheimer’s Disease Research Funding (Million US$), 2011 - 2016
Figure 9-2: National Institute of Health - Forecast for Alzheimer’s Disease Research Funding (Million US$), 2017 - 2018
Figure 9-3: Alzheimer’s Association - Alzheimer’s Disease Research Funding (Million US$), 2011 - 2016
Figure 9-4: Cure Alzheimer’s Fund - Alzheimer’s Disease Research Funding (Million US$), 2008 - 2016
Figure 9-5: Alzheimer’s Drug Discovery Foundation - Alzheimer’s Disease Research Funding (Million US$), 2008 - 2016
Figure 10-1: Worldwide - Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
Figure 10-2: Worldwide - Old-Age Dependency Ratio: Major Areas, 2009 & 2050
Figure 10-3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 - 2050
Figure 10-4: Global - Forecast for Alzheimer’s Disease Pipeline Drugs Market (Million US$), 2019 - 2021
Figure 11-1: Unsuccessful Alzheimer’s Drug Development (Number), 1998 - 2011
LIST OF TABLES:
Table 3-1: Country Wise - Alzheimer’s Disease Drugs Market Share (Percent), 2013 - 2016
Table 3-2: Country Wise - Forecast for Alzheimer’s Disease Drugs Market Share (Percent), 2017 - 2021
Table 7-1: Alzheimer's Disease Drug Development - Agents Currently in Phase I of Development, (As of May 2017)
Table 7-2: Alzheimer's Disease Drug Development - Agents Currently in Phase II of Development, (As of May 2017)
Table 7-3: Alzheimer's Disease Drug Development - Agents Currently in Phase III of Development, (As of May 2017)
Table 7-4: Alzheimer's Disease - Immunotherapies in Clinical Trials for Alzheimer's Disease, (As of May 2017)
Table 8-1: Global Alzheimer’s Disease Drugs Market - Strategic Alliance, 2003 - 2015
Table 8-2: Global Alzheimer’s Disease Drugs Market - Licensing Agreement, 2007 - 2017
Table 8-3: Global Alzheimer’s Disease Drugs Market - Collaboration Deals, 2005 - 2017
Table 8-4: Global Alzheimer’s Disease Drugs Market - Mergers and Acquisitions, 2008 - 2016
Table 9-1: BrightFocus Foundation - Alzheimer’s Disease Research Funding (Million US$), 2010 - 2016
Table 10-1: Global - Ageing Indicators (Percent), 2011/2012 - 2050
Table 10-2: Global - Population (Number), 2011/2012 - 2050
Table 10-3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100(Medium Variant)
Table 3-1: Country Wise - Alzheimer’s Disease Drugs Market Share (Percent), 2013 - 2016
Table 3-2: Country Wise - Forecast for Alzheimer’s Disease Drugs Market Share (Percent), 2017 - 2021
Table 7-1: Alzheimer's Disease Drug Development - Agents Currently in Phase I of Development, (As of May 2017)
Table 7-2: Alzheimer's Disease Drug Development - Agents Currently in Phase II of Development, (As of May 2017)
Table 7-3: Alzheimer's Disease Drug Development - Agents Currently in Phase III of Development, (As of May 2017)
Table 7-4: Alzheimer's Disease - Immunotherapies in Clinical Trials for Alzheimer's Disease, (As of May 2017)
Table 8-1: Global Alzheimer’s Disease Drugs Market - Strategic Alliance, 2003 - 2015
Table 8-2: Global Alzheimer’s Disease Drugs Market - Licensing Agreement, 2007 - 2017
Table 8-3: Global Alzheimer’s Disease Drugs Market - Collaboration Deals, 2005 - 2017
Table 8-4: Global Alzheimer’s Disease Drugs Market - Mergers and Acquisitions, 2008 - 2016
Table 9-1: BrightFocus Foundation - Alzheimer’s Disease Research Funding (Million US$), 2010 - 2016
Table 10-1: Global - Ageing Indicators (Percent), 2011/2012 - 2050
Table 10-2: Global - Population (Number), 2011/2012 - 2050
Table 10-3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100(Medium Variant)
